159 related articles for article (PubMed ID: 34139703)
1. Association of Immunosuppressants with Mortality of Patients with Bullous Pemphigoid: A Nationwide Population-Based Cohort Study.
Wu CY; Wu CY; Li CP; Lin YH; Chang YT
Dermatology; 2022; 238(2):378-385. PubMed ID: 34139703
[TBL] [Abstract][Full Text] [Related]
2. Association of bullous pemphigoid and comorbid health conditions: a case-control study.
Lee S; Rastogi S; Hsu DY; Nardone B; Silverberg JI
Arch Dermatol Res; 2021 Jul; 313(5):327-332. PubMed ID: 32647978
[TBL] [Abstract][Full Text] [Related]
3. Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study.
Chang TH; Wu CY; Chang YT; Lyu YS; Wu CY
Acta Derm Venereol; 2023 Jun; 103():adv5329. PubMed ID: 37272362
[TBL] [Abstract][Full Text] [Related]
4. Risk of All-Cause Mortality, Cardiovascular Disease Mortality, and Cancer Mortality in Patients With Bullous Pemphigoid.
Shen WC; Chiang HY; Chen PS; Lin YT; Kuo CC; Wu PY
JAMA Dermatol; 2022 Feb; 158(2):167-175. PubMed ID: 34964804
[TBL] [Abstract][Full Text] [Related]
5. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan.
Ho YH; Hu HY; Chang YT; Li CP; Wu CY
J Dermatol; 2019 Jul; 46(7):604-609. PubMed ID: 31062428
[TBL] [Abstract][Full Text] [Related]
7. Association between bullous pemphigoid and risk of venous thromboembolism: A nationwide population-based cohort study.
Chen CL; Wu CY; Lyu YS; Chou YJ; Chang YT; Wu CY
J Dermatol; 2022 Aug; 49(8):753-761. PubMed ID: 35491650
[TBL] [Abstract][Full Text] [Related]
8. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study.
Chen CT; Hu HY; Chang YT; Li CP; Wu CY
Br J Dermatol; 2019 Mar; 180(3):553-558. PubMed ID: 30216411
[TBL] [Abstract][Full Text] [Related]
9. Increased Risk of Bullous Pemphigoid after First-Ever Stroke: A Population-Based Study.
Shen AL; Lin HL; Lin HC; Tseng YF; Hsu CY; Chou CY
Neurodegener Dis; 2017; 17(4-5):166-170. PubMed ID: 28467996
[TBL] [Abstract][Full Text] [Related]
10. The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study.
Kridin K; Schonmann Y; Weinstein O; Schmidt E; Ludwig RJ; Cohen AD
J Am Acad Dermatol; 2021 Jul; 85(1):79-87. PubMed ID: 33744354
[TBL] [Abstract][Full Text] [Related]
11. Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study.
Wu CY; Hu HY; Chou YJ; Li CP; Chang YT
Am J Clin Dermatol; 2020 Aug; 21(4):591-597. PubMed ID: 31820332
[TBL] [Abstract][Full Text] [Related]
12. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Study of Patient-Reported Data of Bullous Pemphigoid and Mucous Membrane Pemphigoid From a US-Based Registry.
Lee J; Seiffert-Sinha K; Attwood K; Sinha AA
Front Immunol; 2019; 10():2219. PubMed ID: 31608053
[TBL] [Abstract][Full Text] [Related]
14. Association between sodium-glucose co-transporter 2 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a nationwide population-based cohort study.
Ma SH; Wu CY; Lyu YS; Chou YJ; Chang YT; Wu CY
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1318-1324. PubMed ID: 35344615
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
Cugno M; Marzano AV; Bucciarelli P; Balice Y; Cianchini G; Quaglino P; Calzavara Pinton P; Caproni M; Alaibac M; De Simone C; Patrizi A; Cozzani E; Papini M; Tedeschi A; Berti E; Rosendaal FR;
Thromb Haemost; 2016 Jan; 115(1):193-9. PubMed ID: 26245987
[TBL] [Abstract][Full Text] [Related]
16. [Bullous pemphigoid: a review].
Bernard P; Charneux J
Ann Dermatol Venereol; 2011 Mar; 138(3):173-81. PubMed ID: 21397147
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatments for bullous pemphigoid.
Garrido PM; QueiróS CS; Travassos AR; Borges-Costa J; Filipe P
J Dermatolog Treat; 2022 Mar; 33(2):649-661. PubMed ID: 32536232
[TBL] [Abstract][Full Text] [Related]
18. Association between bullous pemphigoid and atopic dermatitis: a population-based case-control study in Taiwan.
Wu PC; Wu CY; Lyu YS; Chang YT; Wu CY
Arch Dermatol Res; 2023 Apr; 315(3):419-427. PubMed ID: 35834038
[TBL] [Abstract][Full Text] [Related]
19. Association between chronic kidney disease and risk of bullous pemphigoid: a nationwide population-based cohort study.
Yu WT; Ma SH; Wu CY; Chen YL; Chang YT; Wu CY
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1480-1487. PubMed ID: 37830438
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
